The Swiss company 'Ely Lilly' announced mixed results for the fourth quarter on Thursday. Sales of its well-known weight loss drug Zepbound and diabetes medication Mounjaro rose, but financial indicators declined.
"We are pleased to report a significant increase in sales volumes of Zepbound and Mounjaro in the last quarter. These products are very popular with our clients," said a company representative.
However, despite the sales growth, the company faced a decrease in financial indicators. "We are analyzing the situation to understand what steps need to be taken to improve our financial performance in the next quarter," he added.
